Topical alprostadil in the treatment of female sexual arousal disorder: A pilot study

This study evaluated the efficacy and safety of three doses of topical alpr ostadil* USP (prostoglandin E-1) cream in 8 patients with Female Sexual Aro usal Disorder (FSAD). Each patient tvas administered a single intravaginal dose of placebo followed by, escalating intravaginal doses of the active dr ug at 2-week intervals, Alprostadils effectiveness in enhancing subjective and physiological arousal during visual sexual stimulation was supported by patient ratings and physician assessments of vaginal erythema and transuda te volume. Photoplethysmography measurement of vaginal pulse amplitude was not able to demonstrate treatment sensitivity in the present study. Adverse events included mild cases of vaginal itching and burning. The data suppor t further investigation of the use of alprostadil for FSAD.